key: cord-0758160-ot8kf7oq
authors: Anichini, Gabriele; Terrosi, Chiara; Gandolfo, Claudia; Gori Savellini, Gianni; Fabrizi, Simonetta; Miceli, Giovanni B.; Cusi, M. Grazia
title: SARS-CoV-2 Antibody Response in Persons with Past Natural Infection
date: 2021-04-14
journal: N Engl J Med
DOI: 10.1056/nejmc2103825
sha: 1e0b228f463715c808bf038bee29e7b692152586
doc_id: 758160
cord_uid: ot8kf7oq

nan

 1   Table of 

In this current observational cohort study, we enrolled 100 healthcare workers from 'Santa Maria alle 29

Scotte' University Hospital in Siena. They had been subjected to periodical control (every 2 weeks) by 30 molecular testing for SARS-CoV-2 virus with nasopharyngeal swab. All subjects were from Siena area, 31 healthy and without any pathology. Among them, 38 subjects had a past COVID-19 diagnosis, confirmed 32 both by PCR (between March and December 2020, average 111 days before vaccination) and by serological 33 testing, using SARS-CoV-2 nucleocapsid protein as antigen. Prior to vaccination, they were also tested 34 for the presence of specific humoral response. The sera had a low or undetectable anti-RBD IgG with a mean 35 of 420.7 AU/ml (CI 95% 322.0-519.0; range from 50.0 to 40000 AU/ml). The other group consisted of 62 36 subjects, never infected by SARS-CoV-2. All subjects were vaccinated with BioNTech COVID-19 vaccine 37 (Pfizer Inc.). In order to evaluate the humoral response induced by the vaccine, a blood sample was drawn 38 ten days after vaccine administration. The vaccine consisted of a single dose for people with a past infection 39 and a second dose for naïves. After vaccination, the most common symptoms observed in previously infected 40 people were diffuse pain, fever (>38°C) and asthenia, as the ones they experienced during their disease, 41 while mild to moderate reactions to the vaccine were recorded in naïves. 

Subjects' sera were analyzed ten days after vaccination using Abbott SARS-CoV-2 IgG II Quant assay 54 In addition, a regression analysis of the neutralizing antibodies of pre-infected subjects and naïves was 75 assessed after vaccination, according to their age. Although a slight decrease of antibodies was evidenced in 76 both groups, the linear regression lines showed the same slope, indicating that the difference between 77 neutralizing antibodies in pre-infected and naïve subjects was age-independent ( Figure S1 ). 78 79 Statistical analysis 80 evaluated and statistical significances were assessed with two-tailed chi-squared test. Results were 82 considered statistically significant at p<0.05. For each variable, 95% confidence interval (CI 95%) has been 83 calculated and reported. Regression analysis of the neutralizing antibodies according to the participants' age 84 the age was assessed. All analyses were performed by using Graph Pad Prism software. 

A simple method of estimating fifty per cent endpoints

Antibody response to SARS-CoV-2 in infected patients 101 with different clinical outcome

We thank Prof. Marco Mugnaini from University of Siena for the support in the statistical analysis revision. 96 97